Enfortumab Vedotin–related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature

Enfortumab vedotin (EV) is an antibody-drug conjugate approved for the treatment of refractory advanced urothelial cancer. Cutaneous toxicity is well described but has not been correlated with response. In this retrospective single-center study, data from patients treated with more than one dose of...

Descripción completa

Detalles Bibliográficos
Autores principales: Vlachou, Evangelia, Matoso, Andres, McConkey, David, Jing, Yuezhou, Johnson, Burles Avner, Hahn, Noah M., Hoffman-Censits, Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Brief Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937876/
https://www.ncbi.nlm.nih.gov/pubmed/36820243
http://dx.doi.org/10.1016/j.euros.2023.01.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937876/
https://www.ncbi.nlm.nih.gov/pubmed/36820243
http://dx.doi.org/10.1016/j.euros.2023.01.002

Ejemplares similares